CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income	Accumulated Deficit	Total
Balances at beginning of period at Dec. 31, 2020	$ 3	$ 392,322	$ 13	$ (81,724)	$ 310,614
Balances at beginning of period (in shares) at Dec. 31, 2020	34,383,719
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options		225			225
Issuance of common stock upon exercise of stock options (in shares)	62,197
Vesting of restricted common stock from early-exercised stock options		21			21
Stock-based compensation expense		2,000			2,000
Net loss				(16,086)	(16,086)
Unrealized gain (loss) on marketable securities			28		28
Balances at end of period at Mar. 31, 2021	$ 3	394,568	41	(97,810)	296,802
Balances at end of period (in shares) at Mar. 31, 2021	34,445,916
Balances at beginning of period at Dec. 31, 2020	$ 3	392,322	13	(81,724)	310,614
Balances at beginning of period (in shares) at Dec. 31, 2020	34,383,719
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss					(61,732)
Unrealized gain (loss) on marketable securities					(26)
Balances at end of period at Sep. 30, 2021	$ 3	399,690	(13)	(143,456)	256,224
Balances at end of period (in shares) at Sep. 30, 2021	34,492,507
Balances at beginning of period at Mar. 31, 2021	$ 3	394,568	41	(97,810)	296,802
Balances at beginning of period (in shares) at Mar. 31, 2021	34,445,916
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options		28			28
Issuance of common stock upon exercise of stock options (in shares)	7,323
Vesting of restricted common stock from early-exercised stock options		5			5
Stock-based compensation expense		2,456			2,456
Net loss				(22,740)	(22,740)
Unrealized gain (loss) on marketable securities			(23)		(23)
Balances at end of period at Jun. 30, 2021	$ 3	397,057	18	(120,550)	276,528
Balances at end of period (in shares) at Jun. 30, 2021	34,453,239
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options		140			140
Issuance of common stock upon exercise of stock options (in shares)	39,268
Vesting of restricted common stock from early-exercised stock options and sales of restricted common stock		5			5
Stock-based compensation expense		2,488			2,488
Net loss				(22,906)	(22,906)
Unrealized gain (loss) on marketable securities			(31)		(31)
Balances at end of period at Sep. 30, 2021	$ 3	399,690	(13)	(143,456)	256,224
Balances at end of period (in shares) at Sep. 30, 2021	34,492,507
Balances at beginning of period at Dec. 31, 2021	$ 3	402,244	(202)	(168,395)	233,650
Balances at beginning of period (in shares) at Dec. 31, 2021	34,498,443
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options		220			220
Issuance of common stock upon exercise of stock options (in shares)	107,060
Vesting of restricted common stock from early-exercised stock options		4			4
Stock-based compensation expense		2,626			2,626
Net loss				(26,983)	(26,983)
Unrealized gain (loss) on marketable securities			(533)		(533)
Balances at end of period at Mar. 31, 2022	$ 3	405,094	(735)	(195,378)	208,984
Balances at end of period (in shares) at Mar. 31, 2022	34,605,503
Balances at beginning of period at Dec. 31, 2021	$ 3	402,244	(202)	(168,395)	233,650
Balances at beginning of period (in shares) at Dec. 31, 2021	34,498,443
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss					(67,653)
Unrealized gain (loss) on marketable securities					(540)
Balances at end of period at Sep. 30, 2022	$ 4	417,624	(742)	(236,048)	180,838
Balances at end of period (in shares) at Sep. 30, 2022	36,932,597
Balances at beginning of period at Mar. 31, 2022	$ 3	405,094	(735)	(195,378)	208,984
Balances at beginning of period (in shares) at Mar. 31, 2022	34,605,503
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options		21			21
Issuance of common stock upon exercise of stock options (in shares)	21,095
Vesting of restricted common stock from early-exercised stock options		4			4
Stock-based compensation expense		2,759			2,759
Issuance of common stock from at the market offering, net of issuance costs of $0.3 million	$ 1	7,188			7,189
Issuance of common stock from at the market offering, net of issuance costs of $0.3 million (in shares)	2,272,727
Net loss				(20,831)	(20,831)
Unrealized gain (loss) on marketable securities			(176)		(176)
Balances at end of period at Jun. 30, 2022	$ 4	415,066	(911)	(216,209)	197,950
Balances at end of period (in shares) at Jun. 30, 2022	36,899,325
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options		56			56
Issuance of common stock upon exercise of stock options (in shares)	33,272
Vesting of restricted common stock from early-exercised stock options		3			3
Stock-based compensation expense		2,499			2,499
Net loss				(19,839)	(19,839)
Unrealized gain (loss) on marketable securities			169		169
Balances at end of period at Sep. 30, 2022	$ 4	$ 417,624	$ (742)	$ (236,048)	$ 180,838
Balances at end of period (in shares) at Sep. 30, 2022	36,932,597